NASDAQ:EXEL

Exelixis - EXEL Stock Forecast, Price & News

$15.68

-0.16 (-1.01%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $15.65
▼
$16.17
50-Day Range: $15.68
▼
$21.55
52-Week Range: $15.50
▼
$23.40

Volume: 2.95 million shs
Average Volume: 1.96 million shs
Market Capitalization: $5.05 billion

P/E Ratio: 18.67
Dividend Yield: N/A
Price Target: $29.88

Exelixis MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 90.5% Upside
$29.88 Price Target
Short Interest: Healthy
2.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.63
Upright™ Environmental Score
News Sentiment: 0.34
Based on 12 Articles This Week
Insider Trading: Selling Shares
$717,600 Sold Last Quarter
Proj. Earnings Growth: 40.91%
From $0.88 to $1.24 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.07 out of 5 stars

Medical Sector

18th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

1st out of 171 stocks

3.4

Analyst's Opinion

Consensus Rating
Exelixis has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.88, Exelixis has a forecasted upside of 90.5% from its current price of $15.68.
Amount of Analyst Coverage
Exelixis has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.92% of the outstanding shares of Exelixis have been sold short.
Short Interest Ratio / Days to Cover
Exelixis has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Exelixis has recently decreased by 3.49%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Exelixis does not currently pay a dividend.
Dividend Growth
Exelixis does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exelixis has received a 64.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "VEGFR tyrosine kinase inhibitors", "Mitogen-activated protein kinase (MEK) inhibitors", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Exelixis is -1.63.

1.9

News and Social Media Coverage

News Sentiment
Exelixis has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Exelixis this week, compared to 6 articles on an average week.
Search Interest
Only 13 people have searched for EXEL on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $717,600.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Exelixis is held by insiders.
Percentage Held by Institutions
85.25% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Exelixis are expected to grow by 40.91% in the coming year, from $0.88 to $1.24 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exelixis is 18.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.40.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exelixis is 18.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.14.
Price to Earnings Growth Ratio
Exelixis has a PEG Ratio of 0.50. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Exelixis has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

October 1, 2022 | nasdaq.com

Nasdaq Bear Market: 5 Amazing Growth Stocks You'll Regret Not Buying on the Dip - Nasdaq

October 1, 2022 | investing.com

Exelixis Earnings, Revenue Beat in Q4 By Investing.com - Investing.com

October 1, 2022 | fool.com

Nasdaq Bear Market: 5 Amazing Growth Stocks You'll Regret Not Buying on the Dip - The Motley Fool

October 1, 2022 | ca.investing.com

Exelixis Earnings, Revenue beat in Q4 By Investing.com - Investing.com Canada

September 29, 2022 | nasdaq.com

3 Biotech Stocks to Buy and Hold for the Next 10 Years - Nasdaq

September 28, 2022 | markets.businessinsider.com

American Liver Foundation Hosts Free Liver Cancer Conference for Patients and Families

September 28, 2022 | reuters.com

EXEL.O - Exelixis, Inc. | Stock Price & Latest News | Reuters

September 28, 2022 | businesswire.com

Dr Karin Schmitt joins Mursla as Chief Operating Officer - Business Wire

September 26, 2022 | nasdaq.com

2 No-Brainer Biotech Stocks to Buy Right Now - Nasdaq

September 24, 2022 | fool.com

3 Monster Stocks in the Making - The Motley Fool

September 22, 2022 | americanbankingnews.com

Analysts Set Exelixis, Inc. (NASDAQ:EXEL) PT at $30.56

September 20, 2022 | nasdaq.com

2 Growth Stocks That Could Double in the Next Year - Nasdaq

September 18, 2022 | nasdaq.com

First Week of EXEL May 2023 Options Trading

September 15, 2022 | seekingalpha.com

Exelixis: Efforts Continue To Diversify The Pipeline

September 15, 2022 | seekingalpha.com

Exelixis: Efforts Continue To Diversify The Pipeline (NASDAQ:EXEL) - Seeking Alpha

September 14, 2022 | finance.yahoo.com

Exelixis (NASDAQ:EXEL) investors are sitting on a loss of 39% if they invested five years ago

September 13, 2022 | nasdaq.com

First Week of January 2025 Options Trading For Exelixis (EXEL) - Nasdaq

September 12, 2022 | businesswire.com

Leukemia Therapeutics Global Market Report 2022: A $20+ Billion Market in 2026 - Long-term Forecast to 2031 - ResearchAndMarkets.com - Business Wire

September 12, 2022 | finance.yahoo.com

Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients

September 10, 2022 | bloomberg.com

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an - Bloomberg

September 10, 2022 | finance.yahoo.com

Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

September 9, 2022 | businesswire.com

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 - Business Wire

September 9, 2022 | nasdaq.com

Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report? - Nasdaq

September 8, 2022 | benzinga.com

Exelixis (NASDAQ:EXEL) – Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kid - Benzinga

September 8, 2022 | finance.yahoo.com

Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings: 8/09/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:EXEL
CUSIP: 30161Q10
CIK: 939767
Web: www.exelixis.com
Phone: (650) 837-7000
Fax: 650-837-8300
Employees: 954
Year Founded: 1994

Price Target and Rating

Average Stock Price Forecast: $29.88
High Stock Price Forecast: $42.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +90.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.84
Trailing P/E Ratio: 18.67
Forward P/E Ratio: 17.82
P/E Growth: 0.5
Net Income: $231.06 million
Net Margins: 17.53%
Pretax Margin: 22.19%
Return on Equity: 12.10%
Return on Assets: 10.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.08
Quick Ratio: 5.97

Sales & Book Value

Annual Sales: $1.43 billion
Price / Sales: 3.52
Cash Flow: $0.77 per share
Price / Cash Flow: 20.48
Book Value: $6.99 per share
Price / Book: 2.24

Miscellaneous

Outstanding Shares: 321,830,000
Free Float: 312,499,000
Market Cap: $5.05 billion
Optionable: Optionable
Beta: 0.65

Social Links

Key Executives

Dr. Stelios Papadopoulos Ph.D. (Age 74)
Co-Founder & Independent Chair of the Board
Comp: $98k

Dr. Michael M. Morrissey Ph.D. (Age 61)
CEO, Pres & Director
Comp: $2.37M

Mr. Christopher J. Senner (Age 54)
Exec. VP & CFO
Comp: $1.09M

Dr. Peter Lamb Ph.D. (Age 61)
Exec. VP of Scientific Strategy & Chief Scientific Officer
Comp: $909.46k

Mr. Jeffrey J. Hessekiel J.D. (Age 53)
Exec. VP, Gen. Counsel & Sec.
Comp: $957.2k

Mr. Patrick J. Haley M.B.A. (Age 46)
MBA, Exec. VP of Commercial
Comp: $846.43k

Dr. Dana T. Aftab Ph.D.
Exec. VP of Bus. Operations

Ms. Susan T. Hubbard
Exec. VP of Public Affairs & Investor Relations

Mr. Gregg Bernier
VP of Marketing

Ms. Laura Dillard
Exec. VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.
What is Exelixis' stock price forecast for 2022?: 7 Wall Street analysts have issued 12 month price objectives for Exelixis' stock. Their EXEL share price forecasts range from $23.00 to $42.00. On average, they anticipate the company's share price to reach $29.88 in the next year. This suggests a possible upside of 90.5% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.
How have EXEL shares performed in 2022?: Exelixis' stock was trading at $18.28 on January 1st, 2022. Since then, EXEL stock has decreased by 14.2% and is now trading at $15.68.
View the best growth stocks for 2022 here.
When is Exelixis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXEL earnings forecast.
How were Exelixis' earnings last quarter?: Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. The biotechnology company earned $419.43 million during the quarter, compared to the consensus estimate of $391.09 million. Exelixis had a net margin of 17.53% and a trailing twelve-month return on equity of 12.10%.
What guidance has Exelixis issued on next quarter's earnings?: Exelixis updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.63 billion, compared to the consensus revenue estimate of $1.59 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?: 75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.
What other stocks do shareholders of Exelixis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).
What is Exelixis' stock symbol?: Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How do I buy shares of Exelixis?: Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Exelixis' stock price today?: One share of EXEL stock can currently be purchased for approximately $15.68.
How much money does Exelixis make?: Exelixis (NASDAQ:EXEL) has a market capitalization of $5.05 billion and generates $1.43 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.84 on an earnings per share basis.
How many employees does Exelixis have?: The company employs 954 workers across the globe.
How can I contact Exelixis?: Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Exelixis - EXEL Stock Forecast, Price & News

Exelixis MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows